Bezuclastinib Tablets (Formulation A) + Bezuclastinib Tablets (Formulation B) + Placebo Tablets
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SSM
Conditions
SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
Trial Timeline
Jun 27, 2022 → Apr 1, 2030
NCT ID
NCT05186753About Bezuclastinib Tablets (Formulation A) + Bezuclastinib Tablets (Formulation B) + Placebo Tablets
Bezuclastinib Tablets (Formulation A) + Bezuclastinib Tablets (Formulation B) + Placebo Tablets is a phase 2 stage product being developed by Cogent Biosciences for SSM. The current trial status is active. This product is registered under clinical trial identifier NCT05186753. Target conditions include SSM, Mastocytosis, Indolent, Mastocytosis, Systemic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05186753 | Phase 2 | Active |
Competing Products
2 competing products in SSM
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MorphaBond ER + Comparator Drug | Daiichi Sankyo | Pre-clinical | 23 |
| Comparator: exenatide + Comparator: exenatide + Comparator: Placebo | Merck | Phase 1 | 33 |